Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA:688443)

China flag China · Delayed Price · Currency is CNY
26.28
-0.56 (-2.09%)
At close: Mar 9, 2026
9.96%
Market Cap 9.64B
Revenue (ttm) 230.72M
Net Income (ttm) -536.22M
Shares Out 366.68M
EPS (ttm) -1.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,254,397
Average Volume 2,960,959
Open 26.57
Previous Close 26.84
Day's Range 25.96 - 26.65
52-Week Range 22.89 - 37.88
Beta 0.71
RSI 38.38
Earnings Date Apr 30, 2026

About SHA:688443

Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondylarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic lupus erythematosus; GR2002 an anti-TSLP bispecific antibody; WM1R3, a family receptor bispecific antibody; GR2001, a monoclonal antibody; GR2201, a mo... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 793
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688443
Full Company Profile

Financial Performance

In 2025, SHA:688443's revenue was 230.72 million, an increase of 666.65% compared to the previous year's 30.09 million. Losses were -536.22 million, -32.74% less than in 2024.

Financial Statements

News

There is no news available yet.